As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Researchers from Southern Medical University have divulged the discovery and preclinical characterization of novel PDE4 inhibitors for the treatment of hepatic sepsis. Synthesis and optimization of a ...
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of ...
Verona Pharma's Ohtuvayre offers a novel dual mechanism of action for COPD at a premium price, presenting market potential ...
In just two neutron experiments, scientists discovered remarkable details about the function of an enzyme that can aid drug ...
Now that there is an approved therapy for seborrheic dermatitis, it is time to give this condition the attention and respect ...
Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...
The scientists, working at the Department of Energy’s Oak Ridge National Laboratory, used neutrons at the Spallation Neutron Source and the High Flux Isotope Reactor to identify exact atomic-scale ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback